[144] Akero Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Akero Therapeutics Form 144 filed for an insider sale of common stock. The notice reports an intended sale of 3,000 common shares with an aggregate market value of $142,371.90 from a total of 79,988,975 shares outstanding. The sale is listed for 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

The filing shows the securities were acquired and exercised on 08/12/2025 via a stock option exercise and paid in cash. It also states "Nothing to Report" for any securities sold during the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Positive

• Full transaction details provided: class, share count, aggregate market value, broker, exchange, and trade date are listed
• Acquisition and payment disclosed: securities were acquired by a stock option exercise on 08/12/2025 and paid in cash
• No other sales reported in the past three months ("Nothing to Report")
• Broker identified: Morgan Stanley Smith Barney LLC is named as the executing broker

Negative

• None.

Insights

Financial Analyst

TL;DR: Small, disclosed insider sale of 3,000 shares executed same day as option exercise; routine Rule 144 filing.

The filing documents a single insider transaction: exercise of stock options and an intended sale of 3,000 Akero common shares valued at $142,371.90, to occur on 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The report indicates no other sales in the prior three months and includes the attestation regarding undisclosed material adverse information. For investors, this is a transparent, routine disclosure of an insider liquidity event rather than a corporate action or financial restatement.

Corporate Governance Expert

TL;DR: Proper Rule 144 disclosure completed; key fields provided though some issuer relationship detail is absent.

The Form 144 provides required transaction details: class, quantity, market value, broker, trade date, and acquisition method (stock option exercise). The filer also confirms no recent sales. The form lists a blank for relationship to the issuer, which is a conspicuous omission in the issuer information section and may limit readers' ability to assess the seller's affiliation from this filing alone. Overall, the form fulfills basic Rule 144 disclosure requirements but lacks some contextual issuer relationship detail.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3000	142371.90	79988975	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/12/2025	Stock Option Exercise	Issuer			3000	08/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Akero Therapeutics (AKRO) report on Form 144?

The Form 144 reports an intended sale of 3,000 common shares valued at $142,371.90, to be sold on 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

How were the shares acquired according to the filing?

The filing states the shares were acquired on 08/12/2025 by stock option exercise, with payment made in cash.

Does the Form 144 show other recent insider sales for AKRO?

No. The filing indicates "Nothing to Report" for securities sold during the past three months.

Which broker is handling the sale in the AKRO Form 144?

The named broker is Morgan Stanley Smith Barney LLC, address listed in the filing.

What share count and outstanding shares are listed on the filing?

The filing lists 3,000 shares to be sold and 79,988,975 shares outstanding.